HAVN Life Sciences

Vancouver-based HAVN Life Sciences is a biotechnology company engaged in the extraction and distribution of psychoactive compounds mainly derived from plant-based sources, and developing natural health care products from such compounds. 

It has two divisions: 1) HAVN Labs—a research facility working on extraction methods, treatment optimization formulations, and formulating microdosing therapies, 2) HAVN Retail—focused on selling natural health products to end consumers and manufacturers. The company supplies psychedelics to the Heroic Hearts Project, a not-for-profit initiative making psychedelic treatments accessible to military veterans suffering from post-traumatic stress disorder (PTSD). 

The company entered into a partnership with Jamaican nutraceutical company Hypha Wellness Jamaica Psilocybin, in March 2021. It has also secured supply agreements with other psychedelic pharmaceutical companies including Cube Psytech and Mycotopia Therapies, to supply psilocybin compounds.

The company expects to secure its Dealer’s Licence in 2021 which will allow the supply and sale of regulated psychedelic compounds. It is currently conducting preclinical trials on its microdosing therapies. 

Founded in 2020, HAVN Life Sciences went public on the Canadian Securities Exchange (CSE) in September 2020. It is also trading on the over-the-counter (OTC) Pink markets under the ticker symbol “HAVLF”.